ADC Therapeutics Plunges 53% as Patient Deaths Mar Zynlonta Trial Results

Key Facts

In a move highlighting the biotech sector's extreme sensitivity to critical clinical data, ADC Therapeutics shares experienced a massive sell-off. The stock plunged 53% in after-hours trading following reports of patient deaths during a Phase III study of its blood cancer drug, Zynlonta. According to reports, these fatalities completely overshadowed the fact that the drug successfully met its primary efficacy goal of improving progression-free survival in treated patients.

This shocking decline comes as the biotechnology industry faces intense scrutiny regarding the balance between drug efficacy and patient safety. Looking at peer performance, companies like Fate Therapeutics have historically seen extreme volatility when clinical toxicity concerns emerge, per market data. Experts suggest that deaths in late-stage trials create significant hurdles for FDA approval pathways, potentially jeopardizing the drug's entire commercial viability.

Traders are currently monitoring technical support levels following this sharp decline, with ADCT trading at significantly depressed levels as of the June 4, 2026 close. Looking ahead at the economic calendar, there are no immediate sector-specific catalysts scheduled, leaving the stock vulnerable to continued selling pressure until the company provides a detailed explanation regarding the trial fatalities.